Review Article

Nitrone-based therapeutics for neurodegenerative diseases: Their use alone or in combination with lanthionines

Robert A. Floyd^{a,*}, Hugo C. Castro Faria Neto^b, Guy A. Zimmerman^{b,c}, Kenneth Hensley^d, Rheal A. Townner^e^a Experimental Therapeutics, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA^b Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, IOC, Fiocruz, Rio de Janeiro, Brazil^c Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA^d Department of Pathology and Department of Neurosciences, University of Toledo Medical Center, Toledo, OH^e Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA

ARTICLE INFO

Available online 16 February 2013

Keywords:

Nitrones
Glioma
Glioblastoma multiforme
Cancer
Dementia
Septic shock
Malaria dementia
Aging
Lanthionine
PBN
NXY-059
OKN-007
Spin trapping
Free radicals

ABSTRACT

The possibility of free radical reactions occurring in biological processes led to the development and employment of novel methods and techniques focused on determining their existence and importance in normal and pathological conditions. For this reason the use of nitrones for spin trapping free radicals became widespread in the 1970s and 1980s, when surprisingly the first evidence of their potent biological properties was noted. Since then widespread exploration and demonstration of the potent biological properties of phenyl-*tert*-butylnitron (PBN) and its derivatives took place in preclinical models of septic shock and then in experimental stroke. The most extensive commercial effort made to capitalize on the potent properties of the PBN-nitrones was for acute ischemic stroke. This occurred during 1993–2006, when the 2,4-disulfonylphenyl PBN derivative, called NXY-059 in the stroke studies, was shown to be safe in humans and was taken all the way through clinical phase 3 trials and then was deemed to be ineffective. As summarized in this review, because of its excellent human safety profile, 2,4-disulfonylphenyl PBN, now called OKN-007 in the cancer studies, was tested as an anti-cancer agent in several preclinical glioma models and shown to be very effective. Based on these studies this compound is now scheduled to enter into early clinical trials for astrocytoma/glioblastoma multiforme this year. The potential use of OKN-007 in combination with neurotropic compounds such as the lanthionine ketamine esters is discussed for glioblastoma multiforme as well as for various other indications leading to dementia, such as aging, septic shock, and malaria infections. There is much more research and development activity ongoing for various indications with the nitrones, alone or in combination with other active compounds, as briefly noted in this review.

© 2013 Elsevier Inc. All rights reserved.

Contents

Why should nitrones be considered potential therapeutics?	146
Spin trapping—history and general considerations	146
Early demonstrations of the biological effects of nitrones	147
PBN-related nitrones for the treatment of stroke	147
Early observations in experimental stroke	147
Commercial development of the novel nitron 2,4-disulfonyl-phenyl- <i>tert</i> -butylnitron (NXY-059) for treatment of acute ischemic stroke ..	147
Anti-cancer activity of the nitron OKN-007 for glioblastoma	148
Glioblastomas	148
General considerations	148
Diagnosis	148
Animal models	148
Gliomas: therapeutic effect of OKN-007	148

* Corresponding author.

E-mail address: robert-floyd@omrf.ouhsc.edu (R.A. Floyd).

Lanthionines—a novel class of neurotropic agents with therapeutic potential to synergize with nitronone neuroprotectants	150
Potential of nitronone therapy in cognitive decline and dementia in aging and after critical illness	150
Cognitive decline and dementia in aging	150
Sepsis-induced dementia	152
Malaria-induced dementia	152
Potential of PBN-nitrones to treat dementia	153
Summary and prospective future directions	153
Acknowledgments	154
References	154

Why should nitrones be considered potential therapeutics?

It is important to ask the question, why are the PBN (α -phenyl-*N*-*tert*-butylnitronone) nitrones considered potential therapeutics? The most important reason is that PBN and some of its congeners have been found to have extremely potent biological activity in several experimental biological systems. Historically, in the late 1960s and early 1970s the nitrones became important agents to aid in the identification of highly unstable free radical intermediates in chemical reactions because they could react with and stabilize free radicals by what was commonly known as a spin trapping reaction. To the surprise of some chemists the nitrones PBN and DMPO (5,5-dimethyl-1-pyrroline-*N*-oxide) also proved to be useful to trap free radicals in biochemical systems. Their use was then extended to biological systems [1]. It was found that extending their use to biological systems became problematic for their intended purpose of identifying the free radical intermediates because the spin adduct nitroxide was chemically reduced by the reductive biological processes and rendered paramagnetic silent. However, it was discovered in several instances that the nitrones had potent biological activity in many biological systems [1,2]. This report presents a summary of the past, present, and future prospects of research and development focused on the therapeutic potential of nitrones.

Spin trapping—history and general considerations

The spin trapping method, named by E.G. Janzen, was developed independently by various researchers in 1968 and 1969 [3–8] to extend the limits of electron spin resonance (ESR) spectroscopy so that lower concentrations of free radicals could be detected indirectly. This method involves the trapping of reactive short-lived free radicals by a diamagnetic spin trap compound via an addition reaction to produce a more stable free radical product or spin adduct. The spin adduct that is formed is paramagnetic and has an ESR spectrum with a hyperfine splitting constant and *g* value characteristic of the type of reactive free radical trapped. Thus, the structure of the radical trapped can usually be deduced, although the most difficult aspect of the spin trapping technique is the correct assignment of the nitroxide spectrum to the original radical species.

Nitrones are commonly used spin trapping agents in biological systems. The addition of a reactive free radical ($R^{\bullet}$) with a nitronone spin trap results in the formation of a nitroxide (see Fig. 1). Nitroxides are stable free radicals because of the resonance stabilization of the unpaired electron between the nitrogen and the oxygen of the nitroxyl functional group [9]. The most stable nitroxides are those with inert functional groups attached to the nitrogen atom, such as methylated carbon atoms [10–12]. Examples of commonly used nitrones are PBN [3] and the cyclic nitronone DMPO [8,13–15]. Interesting derivatives of PBN bound to cyclodextrins, such as permethylated cyclodextrin or 2,6-di-*O*-Me- β -cyclodextrin-grafted PBN, have been found to trap carbon-

oxygen-centered free radicals with enhanced ESR signal intensities [16]. Recently, DMPO and other cyclic nitrones (e.g., AMPO, EMPO, 5-diethoxyphosphoryl-5-methyl-1-pyrroline-*N*-oxide (DEPMPO)) have been assessed for their abilities to trap reactive nitrogen species, such as $\cdot\text{NO}_2$, ONOO^- , and ONOOCO_2^- [17,18]. Improvements in nitrones for the trapping of superoxide ($\text{O}_2^{\bullet-}$) include derivatives of the DEPMPO nitronone, 5-diethoxyphosphoryl-4-hydroxymethyl-5-methyl-1-pyrroline-*N*-oxide, the β -cyclodextrin-cyclic nitronone conjugate 5-*N*- β -cyclodextrin-carboxamide-5-methyl-1-pyrroline *N*-oxide [19], a cyclic nitronone conjugate of calyx[4]pyrrole (CalixMPO) [20], and a 4-furoxanyl nitronone (FxBN) [21]. For the detection of mitochondrial-generated free radicals, a novel cyclic nitronone spin trap containing a phosphonium cation, [4-(2-methyl-1-oxy-3,4-dihydro-2*H*-pyrrole-2-carbonyloxy)-butyl]-triphenylphosphonium bromide, for trapping superoxide and hydroxyl radicals [22], and a nitronone-containing *N*-arylpyridinium salt for trapping carbon-centered radicals [23] could be useful.

The type of spin trap used is an important factor in determining how informative and sensitive the spin trapping technique may be for a given free radical species. It is important to emphasize that no single spin trap is optimal for the trapping of all types of reactive free radicals. The main advantages of using nitronone spin traps are: (i) they are less sensitive to light, oxygen, or water vapor; (ii) they are soluble in a large number of solvents at fairly high concentrations (~ 0.1 M); and (iii) spin adducts are considerably more stable because a carbon atom separates the nitroxide functional group from the trapped radical species [8,24]. The use of nitronone compounds also has some disadvantages such as: (i) the information regarding the nature and structure of the trapped species is difficult to obtain from the spectrum of the spin adduct, e.g., ESR spectra PBN spin adducts have characteristically small $a_{\text{H}\beta}$ (β -hyperfine splitting constant) values with little variation in magnitude among free radical species, although the magnitude of the β -hyperfine splitting is enhanced with the cyclic nitronone DMPO, and (ii) photolysis of PBN in certain solvents (e.g., tetrahydrofuran) rapidly produces spin adducts derived from solvent radicals [8,16]. Reviews of interest

Fig. 1. Spin trapping reaction in which a free radical has reacted with a general PBN-type nitronone to form a spin adduct. In the case of PBN, $A=B=\text{H}$, and with OKN-007, $A=B=\text{SO}_3\text{Na}_2$.

on the chemistry of nitron spin traps and their biological importance are found in Townner [25], Floyd et al. [26,27], Rhodes [28], and Villamena et al. [29].

Recently, in the past decade, it was found that protein radicals generated as a result of oxidative stress processes can be tagged by DMPO to form DMPO–radical adducts, which can be further assessed by immune–spin trapping, a method that utilizes an antibody against DMPO adducts [30–34]. This application has been used very recently in combination with molecular magnetic resonance imaging (MRI) to visualize membrane-bound radicals in various organs/tissues in a diabetes model [35].

Early demonstrations of the biological effects of nitrones

The very first reports that indicated that nitrones had biological activity and suggested that they may act as pharmaceutical agents were done by Novelli et al. in 1985 [36] and 1986 [37]. Novelli confined and subjected rats to trauma brought on by placing them in a rotating drum. He demonstrated that preadministering PBN protected these animals from death. He also demonstrated that preadministration of PBN protected rats from shock trauma caused by administering lipopolysaccharide (LPS). Soon after Novelli reported, in a book chapter, that PBN protected from LPS-induced shock, McKechnie et al. [38] reported results of more extensive studies confirming and expanding upon the primary finding. Hamburger and McCay also reproduced and expanded upon the protective effect of PBN in septic shock as reported in 1989 [39], and then later Pogrebniak et al. [40] explored the role of PBN in mediating blood cytokine downregulation in the rat LPS model when the nitron was administered before shock induction. PBN given after LPS administration was shown not to be protective in this model. As discussed below, during this general time frame we made novel observations that clearly showed PBN had neuroprotective activity in an experimental stroke model.

PBN-related nitrones for the treatment of stroke

Early observations in experimental stroke

In December 1988 we made the novel observation that PBN had neuroprotective activity in experimental ischemic stroke [41–43]. This finding came about serendipitously. We had previously developed the use of salicylate to trap tissue hydroxyl free radicals and demonstrated that they were formed in ischemic/reperfused brains of gerbils [44]. With this result in mind our

initial thought was to use PBN to spin trap and identify possible secondary free radicals that may be formed by the reaction of hydroxyl free radicals with biomolecules such as membrane lipids in the stroked brain. This experiment was tried and it failed to show secondary PBN-trapped radicals using electron spin resonance to monitor these radicals. The use of PBN to trap secondary free radicals failed because the presumptive PBN-trapped free radical adducts were most probably chemically reduced by the reductive systems of biological tissue and hence became nonparamagnetic, and as such thus were electron spin resonance silent. Even though the desired experimental endpoint was not obtained we did discover that PBN-treated animals were protected from stroke even if the PBN was administered up to 1 h after the ischemia/reperfusion insult [41,43]. In addition it was found that older animals were more susceptible to experimental stroke than younger ones; however, if chronic low levels of PBN were administered to the old animals for 2 weeks they became as resistant to the stroke insult as the younger animals. This effect was maintained with nearly the same magnitude at 3 days and was still significant but much less so at 5 days after the last dose of PBN [42,45,46]. The half-life of PBN in animals is about 6 h, so the protective effect could not be due to PBN buildup. These were very novel and surprising results and therefore the discoveries were patented [43]. Our results were quickly confirmed and expanded upon by others [47,48].

Commercial development of the novel nitron 2,4-disulfonyl-phenyl-tert-butyl nitron (NXY-059) for treatment of acute ischemic stroke

Although we have discussed this topic in detail before [26,49,50], it is useful to summarize important aspects of the commercial development of the nitron NXY-059 for treatment of acute ischemic stroke here. Table 1 summarizes the time line and important stages of this effort. Even though PBN showed protection from experimental stroke if given after the ischemia/reperfusion insult the window of opportunity was short. Also the compound had been widely used in academic settings and therefore not novel, either. We discovered that a novel PBN derivative, NXY-059, was much more effective than PBN and showed a much longer window of opportunity for administration after a stroke [49]. In addition it was shown to be an extremely safe compound when administered intravenously to humans even up to 260 μ M and therefore it was chosen to enter into phase 3 clinical trials [49]. This decision was made after extensive studies that showed it to be protective in preclinical models of transient and permanent experimental stroke [49].

Table 1

The time line of major events in the commercial development of NXY-059 for acute ischemic stroke.

1985–1988	Extensive studies on brain ischemia/reperfusion insult (IRI) in gerbils Demonstration of salicylate trapping of hydroxyl free radicals in brain IRI Establishment of time-dependent IRI-mediated brain damage in hippocampus and forebrain
1988	Basic discovery that PBN protected in experimental stroke—December 1988 Discovery patented, basic studies continued, many attempts to license to companies made
1992–1993	Centaur Pharmaceutical, Inc., founded—March 1992 Angel investments made possible, CEO hired Company hires employees, begins to conduct experiments to add value Company explores extent of intellectual property and improves patents for commercial development
1995	Centaur and Astra make codevelopment relationship—June 1995 Studies in stroke and medicinal chemistry for other indications ramped up
1996	NXY-059 chosen as candidate drug for stroke
1996–2002	NXY-059 undergoes extensive toxicology tests and several clinical phase 1 and 2 trials
2002	Renovis, Inc., buys Centaur assets and moves clinical trials forward with AstraZeneca taking lead
2003	NXY-059 phase 3 SAINT-1 efficacy trial begins—May 2003
2005	SAINT-1 trial shows efficacy using modified Rankin test in 1700 patients—May 2005 SAINT-2 trial begins for 3200 patients—July 2005
2006	Analysis of combined SAINT-1 and SAINT-2 trials showed NXY-059 not effective—October 2006

In the first phase 3 clinical trial (SAINT-1), which enrolled about 1700 patients and required 2 years to complete, decode, and analyze the data, the results showed significant efficacy when utilizing the modified Rankin scale as the endpoint parameter. This result prompted the start of a much larger phase 3 trial (SAINT-2) in which about 3200 patients were enrolled. This trial showed no beneficial effect of using NXY-059, and when the data from SAINT-1 and SAINT-2 were pooled and analyzed there was a nonsignificant effect when the window of administration was 6 h or less after the stroke (Table 1).

The testing of NXY-059 for acute ischemic stroke was widely followed and engendered much disappointment and much speculation after its failure, as we have summarized previously [26]. As we discussed previously [50] there may have been a significant fraction of stroke patients helped if MRI characterization of the patients had been an inclusion criterion for screening the patients to be entered into the trial data base. However, the MRI procedure was not in wide use at the time these trials were being designed and carried out.

Anti-cancer activity of the nitrone OKN-007 for glioblastoma

Glioblastomas

General considerations

Forty percent of all primary central nervous system tumors diagnosed are gliomas [51]. Of these, the grade IV glioblastomas (GBMs) are the most malignant, with a survival time of about 15 months for most patients [51], despite current standard-of-care therapeutic approaches. High-grade gliomas (grades III and IV) are the most common primary brain tumors in adults, and their malignant nature ranks them fourth regarding incidence of cancer death [52]. Grading and identification criteria that can be used to provide information regarding tumor behavior include cell proliferation (cellularity and mitotic activity), nuclear atypia, neovascularization, and the presence of necrosis and/or apoptotic regions [53] and may affect therapeutic outcome. Many of these grading and identification criteria can be measured with the use of MRI and MR spectroscopy methods [54,55], which can provide useful information regarding an optimal therapeutic approach.

Current therapies for the treatment of GBM include surgical resection, followed up with radiotherapy and chemotherapy with temozolomide, which has only limited effectiveness [56,57], with an average life span of 14.6 months postdiagnosis [58]. Gamma knife radiosurgery has been used to treat tumor recurrences in select cases and has been successful in prolonging median survival by 8–12 months on average [59]. New targeted therapeutic approaches are classified into functional groups, including inhibitors of growth factors and their receptors, inhibitors of proteins of intracellular signaling pathways, epigenetic gene-expressing mechanisms, inhibitors of tumor angiogenesis, tumor immunotherapy, and vaccines [56]. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, is the only U.S. Food and Drug Administration-approved molecular drug for GBM [60,61]. Unfortunately the use of bevacizumab has improved progression-free survival, but not overall survival [60]. Trials with anti-epidermal growth factor receptor agents have so far failed to show any improved outcomes for GBM [60]. There are other potential therapies that target other signaling pathways, such as heat shock proteins and proteasomes, or multisite kinase inhibitors, that are currently under consideration [60]. Immunotherapies that target key cellular and molecular immune system mediators such as TGF- β , cytotoxic T cells, regulatory T cells, CTLA-4, PD-1, and IDO are also being considered [58]. There are also other approaches being considered that involve the use of microglial cells as therapeutic vectors to

transport genes and/or substances to the tumor site, as well as the use of natural toxins conjugated to drugs that bind to over-expressed receptors in cancer cells [57]. Quite recently, a nitrone compound, OKN-007 (previously known as NXY-059), which has known anti-inflammatory characteristics, is under investigation as an anti-glioma agent in recurrent glioma patients.

Diagnosis

MRI plays an important role as an optimal imaging tool in the diagnostic process for human gliomas. It is commonly used to provide information on brain tumor growth, vasculature, biochemical metabolism, and molecular changes in preclinical glioma models. Morphological MRI (T_2 -weighted or T_1 -weighted contrast-enhanced imaging) is used to provide information on tumor volumes and growth rates, which can be used to distinguish between tumor grades. Tumor morphology can also provide information on tumor invasiveness and necrotic lesions. Necrotic lesions are depicted as dark void regions in a tumor, the volumes of which can be measured from multiple slices [62]. Contrast-enhanced imaging can be used to assess blood–brain barrier disruption; however, this feature can be absent from diffuse infiltrative tumor regions or when assessing therapeutic treatment [63].

Animal models

Animal models provide a means to study disease and pathological processes, as well as the efficacy of potential new therapies. The majority of glioma models involve intracerebral implantation of rodent (rat or mouse) or human glioma cells into synergetic rats or mice or immunocompromised rodents (e.g., nude or athymic rats or mice). Glioma cells are injected into the cerebral cortex of rats or mice (synergetic, if cells are transplanted into the same species and strain that they were obtained from, or immune-compromised rats or mice, if human cells are used) using a stereotaxic device for precise implantation into a brain region. Although no one model emulates all of the characteristics of GBM, they have provided important insight into specific mechanisms of tumor development [64]. Many of these models have some characteristics associated with human gliomas, such as aggressive tumor growth, angiogenesis, and tumor necrosis. The F98 model is currently used by our group as these gliomas have an infiltrative pattern of growth, have attributes associated with human GBM gliomas, and are classified as anaplastic malignant tumors [65,66]. C6 and F98 glioma cell lines were obtained from chemical induction as a result of administering ethylnitrosourea to pregnant rats, the progeny of which developed brain tumors that were isolated and propagated and cloned in cell culture [66], and both are commonly used as preclinical rodent glioma models. Similar to GBM, U87 tumors in immunocompromised rodents are highly cellular with atypia such as mitotic figures and irregular nucleoli and profuse neovascularization; however, unlike GBM, these tumors have a nondiffuse infiltrative growth pattern and a well-demarcated tumor mass surrounded by reactive astrocytes [67].

Gliomas: therapeutic effect of OKN-007

We have previously shown that OKN-007 (previously known as NXY-059) has a dramatic effect on regressing tumor formation in a rat C6 glioma model [68,69]. Morphological MRI was used to calculate tumor volumes (see Fig. 2A, images i–iv, and 2D); diffusion-weighted imaging was used to measure the apparent diffusion coefficient (ADC), which assesses changes in water diffusion due to tissue structural alterations; and perfusion-weighted MRI was used to characterize tissue perfusion rates, which can provide information on alterations in the vascular capillary bed. Rats treated with OKN-007 after tumors were

Fig. 2. Treatment of C6 glioma-bearing rats with OKN-007. (A) Representative MR images of an untreated C6 glioma-bearing rat at 7, 14, 18, and 24 days after intracerebral implantation of rat C6 glioma cells (tumor volumes are 0.0, 23.7, 59.5, and 180.1 mm³, respectively). (B) Representative MR images of an OKN-007-treated C6 glioma at 14, 24, 30, and 40 days after cell implantation (corresponding to 0, 10, 16, and 26 days after initiation of OKN-007 treatment) (tumor volumes are 9.1, 84.5, 71.8, and 2.0 mm³, respectively). (C) Survival curve for untreated ($n=9$) and OKN-007-treated ($n=12$) C6 glioma-bearing rats. There is a significant survival for OKN-007-treated animals ($p < 0.001$). (D) C6 tumor volumes as measured from MR images at days 17–21 for untreated rats ($n=9$; control) and at days 36–40 for OKN-007-treated rats ($n=12$). There is a significant decrease in tumor volumes for OKN-007-treated rats compared to untreated controls ($p < 0.001$).

visualized by MRI were found to have significantly decreased tumor volumes (approx threefold, $p < 0.05$; Fig. 2B, images i–iv, and 2D), decreased ADC ($\sim 20\%$, $p < 0.05$), and increased tissue perfusion rates ($\sim 60\%$, $p < 0.05$) in tumors, compared to untreated rats [68]. Fig. 2D presents a very clear example that tumor volumes were significantly decreased by OKN-007 treatment. The tumor volume was about 150 mm³ at days 15–17 in untreated controls and was about 30 mm³ at days 36–40 in OKN-007-treated rats. It should be noted that the untreated rats could not be kept alive for 36–40 days because of the huge tumor volume and therefore they had to be killed at about 25 days after tumor cell implantation. OKN-007 was administered in the drinking water at 10 mg/kg/day starting when tumors had reached ~ 50 mm³ in volume (about day 15 after intracerebral implantation of rat C6 glioma cells) and continued for a total of 10 days [68]. One group of rats was euthanized after the 10-day treatment period, and a second group was monitored for an additional 25 days after the treatment period [68]. In the cohort of animals that were treated for 10 days and then euthanized, percentage survival was 92% ($p < 0.0001$; Fig. 2C), whereas for the rats that were monitored for an additional 25 days the percentage survival was greater than 80% ($p < 0.001$) [68]. OKN-007 is currently undergoing phase 1/2 clinical trials as a therapy against recurrent GBM.

Currently, the known pharmacological effects of the nitrones are primarily anti-inflammatory, in addition to their ability to scavenge free radicals. The parent nitron compound, PBN, is known to inhibit (1) cyclooxygenase-2, (2) inducible nitric

oxide synthase (iNOS), and (3) nuclear factor κ B (NF- κ B) [26]. OKN-007 has been found to be neuroprotective in a rat transient middle cerebral artery occlusion model for neurological ischemia/reperfusion injury [49]. The neuroprotective effect of OKN-007 has been suggested to be attributable in part to its ability to restore functionality of the brain endothelium [70]. The anti-cancer activity of PBN-nitrones has been potentially attributed to the suppression of nitric oxide production, suppression of iNOS expression, suppression of S-nitrosylation of critical proteins (caspases and Bcl-2, OGG1 DNA repair enzyme, and PTEN tumor suppressor protein, which are respectively involved in shutting down apoptosis, enhanced mutation events, and enhanced Akt-mediated signaling in oncogenesis), and inhibition of NF- κ B activation [27]. We determined previously from immunohistochemistry evaluation that OKN-007 in C6 gliomas decreases cell proliferation (Ki-67) and the basic fibroblast growth factor, which is associated with angiogenesis, as well as increasing apoptosis (m30 antigen), as shown in Fig. 3 [69]. Current investigations are ongoing using microarray and RT-PCR to establish a common target(s) that is responsible for genetic alterations associated with the multiple anti-cancer effect of OKN-007. It is becoming more widely acceptable that single-target agents are not as effective as a combination therapeutic approach. Perhaps nitrones may be more effective as anti-cancer agents when used as single agents that can affect multiple targets or in combination with other single-target agents.

Fig. 3. (A) MRI of an untreated C6 glioma with an outline of the tumor. (B) MRI of an OKN-007-treated C6 glioma depicting a totally regressed tumor. (i) Immunohistochemistry (IHC) of cell proliferation marker, Ki-67, in untreated (left) and OKN-007-treated (right) C6 gliomas. Note decreased cell proliferation after OKN-007 treatment. (ii) IHC of the angiogenesis marker bFGF (basic fibroblast growth factor) in untreated (left) and OKN-007-treated (right) gliomas. Note decreased levels of bFGF in OKN-007-treated IHC slide. (iii) IHC of the apoptosis marker m30 in untreated (left) and OKN-007-treated (right) gliomas. Note increased apoptosis after OKN-007 treatment. Images shown are modified from He et al. [69].

Lanthionines—a novel class of neurotropic agents with therapeutic potential to synergize with nitron neuroprotectants

Lanthionine (L-cysteine-S-β-L-alanine) is a nonproteogenic, natural amino acid found in the mammalian brain and central nervous system. Currently, lanthionine is thought to arise from promiscuous reactivity of *trans*-sulfuration enzymes [71], though we have speculated that the glutathione-binding brain protein lanthionine synthetase-like protein-1 may catalyze lanthionine formation from glutathione [71–73]. Whereas lanthionine itself has no known bioactivities, its natural metabolites may be important lead compounds for neurodegeneration and other conditions. In particular lanthionine is converted to an unusual cyclic thioether, lanthionine ketimine (Fig. 4), through reactions catalyzed by brain kynurenine pathway enzymes [71]. Lanthionine ketimine (LK) and its cell-penetrating ethyl ester, LKE (Fig. 4), possess several intriguing biological activities including the ability to promote growth factor-dependent neurite extension at low-nanomolar concentrations [71,73,74]. Additionally LK and LKE suppress neurotoxic microglial activation [71,73]. Proteomics studies suggest that LK/LKE act, in part through the protein collapsin mediator protein-2, to bring about these biological effects [74]. Additionally, LK/LKE are potent antioxidants and protect cultured neurons against oxidative stress [73]. LKE is orally bioavailable, is brain penetrating, and can be safely administered for weeks to months to laboratory animals [71] (K.H., personal observations).

Lanthionine ketimine derivatives would be logical to consider alone or in combination with nitrones as treatments for both brain tumors and neurodegeneration, because one would anticipate a synergistic benefit from combining the neurotrophic effects of LKE with the neuroprotective effects of PBN. Lanthionines may be especially interesting to consider in the context of

brain tumor therapy, in which radiotherapy can cause undesirable collateral oxidative stress to healthy neurons. Keeping in mind this idea, pilot studies were performed to test LKE's effects in a rat glioma implant model. LKE was administered either intraperitoneally (100 mg/kg/day in saline vehicle) or orally (3 ppt/300 mg/kg/day ad libitum in AIN93G defined rodent chow; Dyets, Inc., Bethlehem, PA, USA) to male Sprague–Dawley rats for 10 days before an intracerebral injection of 100,000 C6 glioma cells into the neocortex. Control rats in the intraperitoneal study received vehicle (saline) injections. In the ad libitum study, control rats received AIN93G diet without drug. In both cases, the treatments continued postimplantation. At 21 days after C6 implantation, brain tumor volumes were assessed by MRI according to published methods [69]. Both intraperitoneal injections of LKE and ad libitum LKE treatments tended to slow the glioma growth, with statistically significant effects observed in the ad libitum group (Fig. 4). Given that PBN can slow glioma growth in the same model [69], there is a compelling rationale to further explore lanthionines as brain tumor treatment agents either alone or in combination with nitron-based therapeutics.

Potential of nitron therapy in cognitive decline and dementia in aging and after critical illness

Cognitive decline and dementia in aging

Cognitive impairment and dementia at older ages commonly result from accumulating vascular and neurodegenerative pathology in the brain and are experienced by more than half of adults age 85 or over [75]. Major risk factors for cognitive impairments in later life include the APOE e4 haplotype, female sex, and head injury [76], but the underlying biological mechanisms are still unclear. Alzheimer disease—a progressive and irreversible

Fig. 4. (A) Structure of natural lanthionine ketimine (LK) and its synthetic ethyl ester, LKE. Both structures naturally exist in tautomeric equilibria, but only the ene-amine form is depicted here. (B) MR image of a growing glioma (postimplantation day 18) seeded into a rat brain, as described in the text, and an analogous image from a sham-injected animal (right) showing the injection track. The boundaries of the tumor in this coronal section are highlighted (the images in this figure and the graphical abstract are modified from Floyd et al. [26]). (C) Oral LKE (3000 ppm/300 mg/kg/day) significantly slowed the growth of implanted C6 gliomas in the rat model. Data were collected at 21 days postimplantation (28 days cumulative dosage with LKE). * $p < 0.05$ by Mann–Whitney test.

neurodegenerative disorder—is the most common form of dementia among older adults, affecting more than 4 million people in the United States and almost 30 million worldwide [77]. Furthermore, a growing consensus is emerging that neurocognitive declines are common, long lasting, and probably permanent for patients who have been critically ill with sepsis, acute respiratory distress syndrome (ARDS), and multiple organ failure [78].

Although these are seemingly distinct scenarios and groups of patients, one must ask whether common features exist among these and potentially other populations of patients experiencing cognitive decline. Aside from generally affecting older people, these conditions of decreased cognition also share a paucity of effective therapeutic or prophylactic measures as a troublesome characteristic.

No theory has been widely accepted to explain the aging process. However, the oxidative stress hypothesis proposed by D. Harman in 1956—the free radical theory of aging—offers an appealing

mechanistic explanation of aging and age-related diseases [79,80]. Harman's theory posits a single process modified by genetic and environmental factors that is responsible for aging and age-related diseases. The central idea is that aging is primarily the result of cumulative damage to macromolecules resulting from free radical attacks—

oxidative stress—originating mainly from mitochondrial processes [79–81]. Although fast-replicating cells with low levels of oxygen consumption are less susceptible to free radical damage, highly differentiated cells with high levels of oxygen consumption are more vulnerable to oxidative stress [80].

Brain function is almost totally dependent on a continuous supply of glucose and oxygen from the arterial circulation. Although the brain represents only 2% of the body weight, it receives 15% of the cardiac output and consumes 20% of total body oxygen and 25% of total body glucose. Neurotransmission and ionic homeostasis account for most of the brain energy expenditure. Glutamate reuptake by astrocytes is a key event

required to maintain brain homeostasis. The entry of glutamate into astrocytes is coupled to the activation of the Na^+/K^+ ATPase pump to normalize ionic gradients across plasma membranes in an ATP-dependent manner [82]. Thus, glutamatergic neurotransmission accounts for a considerable part of energy consumption in the brain. Among the brain cell types, neurons are the most oxygen-dependent cells and numerous studies demonstrate a strong metabolic cooperation between astrocytes and neurons in terms of neurotransmitter reuptake, oxidative stress defense, and energy substrate delivery. Furthermore, all of these processes are critically dependent on energy metabolism [83]. Consequently, neurons, as highly specialized and oxygen-dependent cells, are especially vulnerable to mitochondrial damage by free radicals [84]. Thus, the detrimental effects of the aging process are pronounced in the brain, where irreversibly damaged cells cannot be replaced.

Sepsis-induced dementia

Experimental and clinical evidence indicates that multiple organ dysfunction in sepsis is associated with increased production of reactive oxidant species and depletion of antioxidants, leading to oxidative stress. Reactive oxygen species are frequently associated with endothelial cell injury, blood–brain barrier disruption, recruitment of neutrophils, lipid peroxidation, and oxidative modifications of target proteins in sepsis [85]. Ascorbate levels were significantly lower in cerebrospinal fluid in patients with septic encephalopathy, being correlated with the severity of neurologic symptoms [86]. Oxidative stress is also implicated in pathophysiological mechanisms of cognitive impairment that is detected in over 60% of the patients that survive critical illness such as ARDS and sepsis. These are usually patients over 60 years of age, and they frequently have long-lasting, and perhaps permanent, cognitive decline after being released from the intensive care unit. Importantly, cognitive sequelae are predicted by the duration of delirium, as a manifestation of sepsis-associated encephalopathy, during the acute phase of the disease [87]. Although the clinical evidence is limited because of ethical dilemmas, experimental data using the cecum ligation and puncture (CLP) rodent model of sepsis show that there is an increase in superoxide, nitrites, and lipid peroxide content in the brain capillaries as long as 48 h after induction of sepsis and that glutathione concentration is significantly decreased even at longer times [88]. Importantly, it seems that the hippocampus is especially sensitive to oxidative stress because evidence for oxidative damage can be detected even at 10 days after the induction of sepsis in this brain region, but not in others [89]. Importantly, antioxidant treatment appears to protect mice from oxidative damage and death [90]. The most robust evidence linking oxidative damage and long-term cognitive impairment comes from animal studies. Barichello and co-workers [91] demonstrated that the combined administration of the antioxidants *N*-acetylcysteine and deferoxamine during the acute phase of sepsis induced by the CLP model prevented oxidative damage and long-term cognitive decline. Similarly, antioxidants including vitamins E and C can enhance learning and memory and prevent memory deficits in other experimental conditions including Alzheimer disease, aging, and menopause [92].

Inflammation is another key player in the cognitive decline of neurodegenerative diseases and after critical illness. In fact, chronic low-level inflammation has been proposed as a major mechanism underlying cognitive decline and dementia and has been implicated in the neuropathological cascade leading to the late onset of Alzheimer disease [93,94]. Proinflammatory cytokines can modulate energy metabolism and oxidative stress defense by astrocytes, which may contribute to increased neuronal vulnerability and neurodegeneration (see above). In patho-

logical conditions associated with neuroinflammation, such as in sepsis-associated encephalopathy, excitatory glutamatergic neurotransmission may be increased and this can be the cause of a bioenergetic crisis involving mitochondrial activity and can directly affect brain function [95]. Neuroinflammation is also linked to cell death that may occur by apoptosis or by necrosis due to hypoxia, oxidative stress, and other cytotoxic factors [95]. Brain imaging studies of septic patients with sepsis-associated encephalopathy detected sites of tissue ischemia and lesions in the white matter, suggesting blood–brain barrier dysfunction [96–98]. MRI studies in experimental sepsis also demonstrated cytotoxic and vasogenic edema as well as neuronal damage during the early phase of sepsis [99].

Malaria-induced dementia

Neuroinflammation and oxidative stress are connected not only to cognitive decline in aged patients with neurodegenerative diseases or after severe systemic infectious/inflammatory syndromes. These two injurious mechanisms also have major roles in patients, particularly children, who develop long-term, and potentially permanent, cognitive impairment after cerebral malaria. Cerebral malaria affects African children with high incidence and high mortality [100,101] and there is substantial evidence that patients who are successfully treated and survive cerebral malaria develop long-term cognitive decline in as much as 26% of the cases [102–105]. Precise identification of molecular mechanisms that underlie sustained cognitive dysfunction after cerebral malaria is yet to be achieved, which makes the development of efficient therapy more challenging. Recent studies provided evidence that neuroinflammation and oxidative stress play fundamental roles in cerebral malaria [106]. In fact, intravascular accumulation of monocytes in the brain has long been observed both in mice [107,108] and in humans [109–111] with cerebral malaria. Furthermore, sequestered monocytes and macrophages are more abundant in pediatric patients with cerebral malaria than in those with noncerebral malaria or nonmalarial encephalopathy [112]. The accumulation of leukocytes in the brains of patients and mice with cerebral malaria is evidence of activation of the cytokine/chemokine cascade, which has been shown in experimental and human studies [106,113]. The expression of monocyte-secreted cytokines and chemokines, such as TNF, CXCL10, CCL2, and RANTES, varies with mouse genotype and correlates with resistance versus susceptibility to disease [113]. Moreover the deletion of adhesion molecules, such as $\alpha\text{M}\beta 2$ or $\alpha\text{D}\beta 2$, was shown to have protective effects in experimental cerebral malaria [114,115] (A. Vieira-de-Abreu et al., manuscript in preparation). In a recent study, Reis et al. [116] obtained clear evidence of oxidative damage of the brain during experimental cerebral malaria and demonstrated that animals that survived experimental malaria after rescue with antimalarial drugs developed a long-term cognitive impairment similar to what is observed in the clinical setting and in experimental or clinical sepsis (see above). Furthermore, administration of two antioxidants in combination, *N*-acetylcysteine and desferrioxamine, as adjunctive treatment together with rescue antimalarial therapy prevented late cognitive impairment and reduced microvascular sequestration in several areas of the brain [116]. Again these results are similar to those of studies with models of polymicrobial sepsis [91].

In light of the results discussed so far, one is compelled to speculate that neuroinflammation and oxidative stress are major events underlying cognitive decline observed in neurodegenerative diseases as well as in patients who survived severe systemic infectious/inflammatory syndromes with cerebral involvement. Although neuroinflammation and oxidative stress may not be the whole story, these events are certainly consequent and common to

a variety of clinical conditions associated with cognitive decline and, therefore, suitable targets for new therapeutic measures. Therefore, the unique antioxidant and anti-inflammatory actions of PBN-nitrones discussed earlier implicate them as a suitable pharmacological strategy to prevent and/or improve the outcome of dementia from various etiologies. Importantly, neuroinflammation and oxidative stress are highly interconnected phenomena for which the cause–consequence relation is difficult to identify. For instance, pathological activation of astrocytes and microglia, a hallmark of neuroinflammation, leads to enhanced production of reactive oxygen and nitrogen species, including H_2O_2 and NOO^- , largely through cytokine-mediated activation of the NADPH oxidase system and induction of iNOS expression [117,118]. On the other hand, highly pro-oxidative stress such as ischemia/reperfusion injury induces activation of microglia, neuroinflammation, and cognitive decline [119]. This situation suggests that efficacious therapeutic measures would probably be achieved only with drugs that interfere with these two central events that operate in neurodegenerative diseases and in patients with severe systemic infectious/inflammatory syndromes.

Potential of PBN-nitrones to treat dementia

The PBN-nitrones provide an excellent example of an agent considered antioxidant, but with independent and potent activity in suppressing neuroinflammation as demonstrated in animal models using the rat kainic acid-induced epileptic-type seizures [120]. PBN-nitrones are also potential modulators of neuroinflammation induced by intracisternal injection of LPS in rats [121]. In these models PBN-nitrones prevented microglia activation, loss of NMDA receptors, and cellular killing in the brain [50].

Testing candidate drugs for prevention of cognitive decline in clinical trials has the potential to yield both mechanistic and therapeutic information, but clinical trials are costly and time consuming and are frequently unpowered to detect less than dramatic benefits. On the other hand, preclinical models of disease are easy to control, provide useful mechanistic information, and are much less expensive and time consuming, although appropriate care must be taken in extending results in rodents and other models to humans. Therefore, candidate drugs for clinical trials should often be first selected on the basis of their results in preclinical models that mimic the cognitive impairment associated with aging or severe systemic inflammatory/infectious syndromes, such as sepsis and cerebral malaria.

Several preclinical models exist for studying dementia and Alzheimer disease with features similar to those of the clinical syndromes. They all have advantages and disadvantages that vary with the experimental protocol to be employed [122–124]. Recently, models suited to the study of the cognitive decline associated with severe systemic inflammatory/infectious syndromes in sepsis and malaria have been reported [91,116]. Characteristically, these models employ animals that developed the acute phase of the disease with documented neuroinflammation and/or cerebral oxidative stress and were rescued by conventional treatment with antibiotics, fluid reposition, or antimalarial drugs. Typically, surviving animals showed no evidence of the acute disease at late time points and were then followed for late cognitive sequelae using specific task or behavioral tests that provided information about learning abilities and various types of memory [91,116]. These models have been used both for mechanistic studies [89,91,116,125–128] and for testing of candidate therapies, particularly antioxidant drugs [91,116,125–127]. These models resemble clinical situations in which patients develop the acute critical illness before starting conventional treatment. In the experimental models, adjuvant candidate drugs may be used in addition to the conventional treatment and cognitive endpoint investigated in survivors at later time

points. One positive and informative aspect of this kind of model is that the animals are no longer under the effect of the candidate drugs when they are tested for cognitive performance, providing direct links, that are mechanistically relevant, between events that took place during the acute phase of the disease and the late cognitive sequelae [91,116,129].

PBN-nitrones make ideal candidates for testing using such experimental models because of their spin trapping and anti-inflammatory activities and because they have low toxicity and are also suitable for multiple dose regimens [50]. Furthermore, Novelli and colleagues showed that PBN-nitrones were active in protecting rats from traumatic shock or LPS injection [36]. Also, PBN-nitrones were reported to protect the brain from damage caused by stroke even if the PBN was administered after the brain was reperfused [41,42]. Furthermore administration of PBN-nitrones protected rats from axonal and neuronal injury induced by intracerebral IL-1 β as indicated by decreased expression of β -amyloid precursor protein. Protection of PBN was linked to attenuated oxidative stress as indicated by decreased elevation of 8-isoprostane content and by the reduced number of 4-hydroxynonenal- or malondialdehyde- or nitrotyrosine-positive cells after IL-1 β exposure. PBN also attenuated IL-1 β -stimulated inflammatory as indicated by the reduced activation of microglia [130]. Together, these observations indicate that PBN-nitrones may play a critical role in modulating brain injury associated with oxidative stress and neuroinflammation and therefore can be considered as a potential therapeutic strategy for dementia that follows severe systemic infectious/inflammatory syndromes. In addition Garcia-Alloza and colleagues [131], using a mouse model of Alzheimer disease (APPswe/PS1dE9 mice) and multiphoton microscopy to assess in vivo the characteristics of senile plaques and neurites in APP mice, provided compelling evidence suggesting that PBN-nitrone therapy can alleviate the neuronal abnormalities of APP mice, showing a straightening effect on curved neurites as was detected as soon as 4 days after commencement of treatment and persisted 15 days after the PBN-nitrone administration was stopped. Senile plaques have been associated with abnormal curvature of nearby neurites [132,133], synaptic loss [134,135], and neuritic dystrophies [136] and these alterations have been shown to be at least partially responsible for the disruption of cortical synaptic integration [137]. These data indicate that amelioration of the neuritic distortions associated with senile plaques by PBN-nitrones is both rapid and long lasting and may have beneficial effects on the progression of Alzheimer disease.

These observations warrant new investigations in this area and open up considerable interest in the potential of PBN-nitrones in neurodegenerative diseases and other age-related diseases and as adjuvant drugs for prevention of cognitive decline in syndromes of cerebral inflammation or infection. In addition, PBN-nitrones should also be considered in combination with *N*-acetylcysteine in models of cognitive impairment after sepsis or malaria, because this combination yielded promising outcomes in experimental noise-related hearing loss [138].

Summary and prospective future directions

This report presents an overview of some of the active research and development efforts that are ongoing using a specific nitrone (OKN-007) for a specific indication (GBM). In addition another potential area in which therapeutics are needed includes dementia, which may be an excellent target indication for specific nitrones and/or for a specific nitrone combined with another compound, such as lanthionine, which can act as a neurotropic agent. Although not presented here, current research and

development efforts at various stages of development are now ongoing in which specific therapeutic nitrones are being targeted for: (a) treatment of noise-induced hearing loss [138–141], (b) treatment for macular dementia [142], and (c) treatment for brain damage and hearing loss caused by explosive blasts [143]. So much research and development focused on nitrones as therapeutics provides optimism that treatment for one or more of the indications discussed above may arise from these efforts.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health (5R37HL044525 to G.A.Z. and R01-AG031553 and R21-NS066279 to K.H.) as well as the Judith and Jean Pape Adams Charitable Foundation. Support from the Oklahoma Center for the Advancement of Sciences and Technology (Grant AR092-049 to R.A.T.) and the Oklahoma Medical Research Foundation (R.A.T. and R.A.F.) is also acknowledged. H.C.C.F.N. is a 1A Researcher from the CNPq and is supported by grants from PRONEX, Rede Malaria, CNPq, and FAPERJ. Some of the authors (R.A.F., R.A.T., and K.H.) are inventors on issued or pending U.S. patents and R.A.F. is a co-founder of Otologic Pharmaceuticals, Inc., which has in commercial development a treatment consisting of a nitron combined with an antioxidant for noise-induced hearing loss.

References

- [1] Floyd, R. A. Protective action of nitron-based free radical traps against oxidative damage to the central nervous system. *Adv. Pharmacol.* **38**:361–378; 1997.
- [2] Floyd, R. A. Nitrones as therapeutics in age-related diseases. *Aging Cell* **5**:51–57; 2006.
- [3] Janzen, E. G.; Blackburn, B. J. Detection and identification of short-lived free radicals by an electron spin resonance trapping technique. *J. Am. Chem. Soc.* **90**:5909–5910; 1968.
- [4] Janzen, E. G.; Blackburn, B. J. Detection and identification of short-lived free radicals by electron spin resonance trapping techniques (spin trapping): photolysis of organolead, -tin, and -mercury compounds. *J. Am. Chem. Soc.* **91**:4481–4490; 1969.
- [5] Forshult, S.; Lagercrantz, C.; Torsell, K. Use of nitroso compounds as scavengers for the study of short-lived free radicals in organic reactions. *Acta Chem. Scand. B* **23**:522–530; 1969.
- [6] Chalfont, G. R.; Perkins, M. J. A probe for homolytic reactions in solution. II. The polymerization of styrene. *J. Am. Chem. Soc.* **90**:7141–7142; 1968.
- [7] Leaver Ramsay, I. H. G.C. Trapping of radical intermediates in the photo-reduction of benzophenone. *Tetrahedron Lett.* **25**:5669–5675; 1969.
- [8] Terabe, S.; Konaka, R. Electron spin resonance studies on oxidation with nickel peroxide: spin trapping of free-radical intermediates. *J. Am. Chem. Soc.* **91**:5655–5657; 1969.
- [9] Janzen, E. G. A critical review of spin trapping in biological systems. In: Pryor, W. A., editor. *Free Radicals in Biology*. San Diego: Academic Press; 1980. p. 115–154.
- [10] Thornalley, P. J. Theory and biological application of the electron spin resonance technique of spin trapping. In: Michelson, A. M., Bannister, J. V., editors. *Life Chemistry Reports*. New York: Harwood Academic; 2010. p. 1–56.
- [11] Janzen, E. G.; Stronks, H. J.; DuBose, C. M.; Poyer, J. L.; McCay, P. B. Chemistry and biology of spin-trapping radicals associated with halocarbon metabolism in vitro and in vivo. *Environ. Health Perspect.* **64**:151–170; 1985.
- [12] Perkins, M. J. Spin trapping. *Adv. Phys. Org. Chem.* **17**:1–64; 1980.
- [13] Iwamura, M.; Inamoto, N. Novel formation of nitroxide radicals by radical addition to nitrones. *Bull. Chem. Soc. Jpn.* **40**:703; 1967.
- [14] Janzen, E. G.; Liu, J. I. P. Radical addition reactions of 5,5-dimethyl-1-pyrroline-1-oxide: ESR spin trapping with a cyclic nitron. *J. Magn. Reson.* **9**:510–512; 1973.
- [15] Iwamura, M.; Inamoto, N. Reactions of nitrones with free radicals. I. Radical 1,3-addition to nitrones. *Bull. Chem. Soc. Jpn.* **43**:856–860; 1970.
- [16] Bardelang, D.; Charles, L.; Finet, J. P.; Jicsinszky, L.; Karoui, H.; Marquet, S. R., et al. Alpha-phenyl-N-tert-butyl-nitron-type derivatives bound to beta-cyclodextrins: syntheses, thermokinetics of self-inclusion and application to superoxide spin-trapping. *Chemistry* **13**:9344–9354; 2007.
- [17] Nash, K. M.; Rockenbauer, A.; Villamena, F. A. Reactive nitrogen species reactivities with nitrones: theoretical and experimental studies. *Chem. Res. Toxicol.* **25**:1581–1597; 2012.
- [18] Chaliel, F.; Hardy, M.; Ouari, O.; Rockenbauer, A.; Tordo, P. Design of new derivatives of nitron DEPMP functionalized at C-4 for further specific applications in superoxide radical detection. *J. Org. Chem.* **72**:7886–7892; 2007.
- [19] Han, Y.; Tuccio, B.; Lauricella, R.; Villamena, F. A. Improved spin trapping properties by beta-cyclodextrin-cyclic nitron conjugate. *J. Org. Chem.* **73**:7108–7117; 2008.
- [20] Kim S.U., Liu Y., Nash K.M., Zweier J.L., Rockenbauer A., Villamena F.A. Fast reactivity of a cyclic nitron-calix[4]pyrrole conjugate with superoxide radical anion: theoretical and experimental studies. *J. Am. Chem. Soc.* (in press).
- [21] Barriga, G.; Olea-Azar, C.; Norambuena, E.; Castro, A.; Porcal, W.; Gerpe, A., et al. New heteroaryl nitrones with spin trap properties: identification of a 4-furoxanyl derivative with excellent properties to be used in biological systems. *Bioorg. Med. Chem.* **18**:795–802; 2010.
- [22] Xu, Y.; Kalyanaraman, B. Synthesis and ESR studies of a novel cyclic nitron spin trap attached to a phosphonium group—a suitable trap for mitochondria-generated ROS? *Free Radic. Res.* **41**:1–7; 2007.
- [23] Robertson, L.; Hartley, R. C. Synthesis of N-arylpyridinium salts bearing a nitron spin trap as potential mitochondria-targeted antioxidants. *Tetrahedron* **65**:5284–5292; 2009.
- [24] Janzen, E. G. Spin trapping. *Acc. Chem. Res.* **4**:31–40; 1971.
- [25] Townner, R. A. Chemistry of spin-trapping. In: Rhodes, C. J., editor. *Toxicology of the Human Environment: the Critical Role of Free Radicals*. New York: Taylor & Francis; 2000. p. 7–24.
- [26] Floyd, R. A.; Kopke, R. D.; Choi, C. H.; Foster, S. B.; Doblas, S.; Townner, R. A. Nitrones as therapeutics. *Free Radic. Biol. Med.* **45**:1361–1374; 2008.
- [27] Floyd, R. A.; Chandru, H. K.; He, T.; Townner, R. Anti-cancer activity of nitrones and observations on mechanism of action. *Anticancer Agents Med. Chem.* **11**:373–379; 2011.
- [28] Rhodes, C. J. Current commentary: can free radicals be good for you? *Sci. Prog.* **94**:451–462; 2011.
- [29] Villamena, F. A.; Das, A.; Nash, K. M. Potential implication of the chemical properties and bioactivity of nitron spin traps for therapeutics. *Future Med. Chem.* **4**:1171–1207; 2012.
- [30] Mason, R. P. Using anti-5,5-dimethyl-1-pyrroline N-oxide (anti-DMPO) to detect protein radicals in time and space with immuno-spin trapping. *Free Radic. Biol. Med.* **36**:1214–1223; 2004.
- [31] Ramirez, D. C.; Gomez Mejiba, S. E.; Mason, R. P. Mechanism of hydrogen peroxide-induced Cu,Zn-superoxide dismutase-centered radical formation as explored by immuno-spin trapping: the role of copper- and carbonate radical anion-mediated oxidations. *Free Radic. Biol. Med.* **38**:201–214; 2005.
- [32] Ramirez, D. C.; Gomez-Mejiba, S. E.; Corbett, J. T.; Deterding, L. J.; Tomer, K. B.; Mason, R. P. Cu,Zn-superoxide dismutase-driven free radical modifications: copper- and carbonate radical anion-initiated protein radical chemistry. *Biochem. J.* **417**:341–353; 2009.
- [33] Detweiler, C. D.; Deterding, L. J.; Tomer, K. B.; Chignell, C. F.; Germolec, D.; Mason, R. P. Immunological identification of the heart myoglobin radical formed by hydrogen peroxide. *Free Radic. Biol. Med.* **33**:364–369; 2002.
- [34] Gomez-Mejiba, S. E.; Zhai, Z.; Akram, H.; Deterding, L. J.; Hensley, K.; Smith, N., et al. Immuno-spin trapping of protein and DNA radicals: "tagging" free radicals to locate and understand the redox process. *Free Radic. Biol. Med.* **46**:853–865; 2009.
- [35] Townner, R. A.; Smith, N.; Saunders, D.; Henderson, M.; Downum, K.; Lupu, F., et al. In vivo imaging of immuno-spin trapped radicals with molecular magnetic resonance imaging in a mouse diabetes model. *Diabetes* **61**:2405–2413; 2012.
- [36] Novelli, G. P.; Angiolini, P.; Tani, R.; Consales, G.; Bordin, L. Phenyl-T-butyl-nitron is active against traumatic shock in rats. *Free Radic. Res. Commun.* **1**:321–327; 1985.
- [37] Novelli, G.; Angiolini, P.; Consales, G.; Lippi, R.; Tani, R. Anti-shock action of phenyl-t-butyl-nitron, a spin trapper. In: Novelli, G. P., Ursini, F., editors. *Oxygen Free Radicals in Shock*. Basel: Karger; 1986. p. 119–124.
- [38] McKechnie, K.; Furman, B. L.; Parratt, J. R. Modification by oxygen free radical scavengers of the metabolic and cardiovascular effects of endotoxin infusion in conscious rats. *Circ. Shock* **19**:429–439; 1986.
- [39] Hamburger, S. A.; McCay, P. B. Endotoxin-induced mortality in rats is reduced by nitrones. *Circ. Shock* **29**:329–334; 1989.
- [40] Pogrebnik, H. W.; Merino, M. J.; Hahn, S. M.; Mitchell, J. B.; Pass, H. I. Spin trap salvage from endotoxemia: the role of cytokine down-regulation. *Surgery* **112**:130–139; 1992.
- [41] Floyd, R. A. Role of oxygen free radicals in carcinogenesis and brain ischemia. *FASEB J.* **4**:2587–2597; 1990.
- [42] Carney, J. M.; Starke-Reed, P. E.; Oliver, C. N.; Landrum, R. W.; Chen, M. S.; Wu, J. F., et al. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitron. *Proc. Natl. Acad. Sci. USA* **88**:3633–3636; 1991.
- [43] Carney J.M., Floyd R.A. Phenyl butyl nitron compositions and methods for treatment of oxidative tissue damage. U.S. Patent 5,025,032, 1-14. 6-18-1991.
- [44] Cao, W.; Carney, J. M.; Duchon, A.; Floyd, R. A.; Chevin, M. Oxygen free radical involvement in ischemia and reperfusion injury to brain. *Neurosci. Lett.* **88**:233–238; 1988.
- [45] Carney, J. M.; Floyd, R. A. Protection against oxidative damage to CNS by alpha-phenyl-tert-butyl nitron (PBN) and other spin-trapping agents: a novel series of nonlipid free radical scavengers. *J. Mol. Neurosci.* **3**:47–57; 1991.

- [46] Floyd, R. A.; Carney, J. M. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. *Ann. Neurol.* **32**:S22–S27; 1992.
- [47] Phillis, J. W.; Clough-Helfman, C. Protection from cerebral ischemic injury in gerbils with the spin trap agent N-tert-butyl- α -phenylnitron (PBN). *Neurosci. Lett.* **116**:315–319; 1990.
- [48] Cao, X.; Phillis, J. W. α -Phenyl-tert-butyl-nitron reduces cortical infarct and edema in rats subjected to focal ischemia. *Brain Res.* **644**:267–272; 1994.
- [49] Maples, K. R.; Green, A. R.; Floyd, R. A. Nitron-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. *CNS Drugs* **18**:1071–1084; 2004.
- [50] Floyd, R. A.; Townner, R. A.; He, T.; Hensley, K.; Maples, K. R. Translational research involving oxidative stress and diseases of aging. *Free Radic. Biol. Med.* **51**:931–941; 2011.
- [51] Central Brain Tumor Registry of the United States 2011 *CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007*. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2011 pp. 54–57.
- [52] Niclou, S. P.; Fack, F.; Rajcevic, U. Glioma proteomics: status and perspectives. *J. Proteomics* **73**:1823–1838; 2010.
- [53] Gudinaeviene, I.; Pranys, D.; Juozaityte, E. Impact of morphology and biology on the prognosis of patients with gliomas. *Medicina (Kaunas)* **40**:112–120; 2004.
- [54] Waldman, A. D.; Jackson, A.; Price, S. J.; Clark, C. A.; Booth, T. C.; Auer, D. P., et al. Quantitative imaging biomarkers in neuro-oncology. *Nat. Rev. Clin. Oncol.* **6**:445–454; 2009.
- [55] Young G.S. Advanced MRI of adult brain tumors. *Neurol. Clin.* **25**:947–973, viii; 2007.
- [56] Polivka Jr. J.; Polivka, J.; Rohan, V.; Topolcan, O.; Ferda, J. New molecularly targeted therapies for glioblastoma multiforme. *Anticancer Res.* **32**:2935–2946; 2012.
- [57] Lima, F. R.; Kahn, S. A.; Soletti, R. C.; Biasoli, D.; Alves, T.; da Fonseca, A. C., et al. Glioblastoma: therapeutic challenges, what lies ahead. *Biochim. Biophys. Acta* **1826**:338–349; 2012.
- [58] Wainwright, D. A.; Nigam, P.; Thaci, B.; Dey, M.; Lesniak, M. S. Recent developments on immunotherapy for brain cancer. *Expert Opin. Emerg. Drugs* **17**:181–202; 2012.
- [59] Thumma, S. R.; Elaimy, A. L.; Daines, N.; Mackay, A. R.; Lamoreaux, W. T.; Fairbanks, R. K., et al. Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature. *Case Rep. Med.* **2012**:545492; 2012.
- [60] Patel, M.; Vogelbaum, M. A.; Barnett, G. H.; Jalali, R.; Ahluwalia, M. S. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. *Expert Opin. Invest. Drugs* **21**:1247–1266; 2012.
- [61] Braghieri, M. I.; Sabbaga, J.; Hoff, P. M. Bevacizumab: overview of the literature. *Expert Rev. Anticancer Ther.* **12**:567–580; 2012.
- [62] Townner, R. A.; Smith, N.; Doblas, S.; Garteiser, P.; Watanabe, Y.; He, T., et al. In vivo detection of inducible nitric oxide synthase in rodent gliomas. *Free Radic. Biol. Med.* **48**:691–703; 2010.
- [63] Waerzeggers, Y.; Monfared, P.; Viel, T.; Winkler, A.; Jacobs, A. H. Mouse models in neurological disorders: applications of non-invasive imaging. *Biochim. Biophys. Acta* **1802**:819–839; 2010.
- [64] Huszthy, P. C.; Daphu, I.; Niclou, S. P.; Stieber, D.; Nigro, J. M.; Sakariassen, P. O., et al. In vivo models of primary brain tumors: pitfalls and perspectives. *Neuro Oncol.* **14**:979–993; 2012.
- [65] Barth, R. F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. *J. Neurooncol.* **36**:91–102; 1998.
- [66] Barth, R. F.; Kaur, B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. *J. Neurooncol.* **94**:299–312; 2009.
- [67] Jacobs, V. L.; Valdes, P. A.; Hickey, W. F.; De Leo, J. A. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. *ASN Neuro.* **3**:e00063; 2011.
- [68] Garteiser, P.; Doblas, S.; Watanabe, Y.; Saunders, D.; Hoyle, J.; Lerner, M., et al. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. *J. Magn. Reson. Imaging* **31**:796–806; 2010.
- [69] He, T.; Doblas, S.; Saunders, D.; Casteel, R.; Lerner, M.; Ritchey, J. W., et al. Effects of PBN and OKN007 in rodent glioma models assessed by ^1H MR spectroscopy. *Free Radic. Biol. Med.* **51**:490–502; 2011.
- [70] Culot, M.; Mysiorek, C.; Renfel, M.; Roussel, B. D.; Hommet, Y.; Vivien, D., et al. Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. *Brain Res.* **1294**:144–152; 2009.
- [71] Hensley, K.; Venkova, K.; Christov, A. Emerging biological importance of central nervous system lantionines. *Molecules* **15**:5581–5594; 2010.
- [72] Chung, C. H.; Kurien, B. T.; Mehta, P.; Mhatre, M.; Mou, S.; Pye, Q. N., et al. Identification of lantionine synthase C-like protein-1 as a prominent glutathione binding protein expressed in the mammalian central nervous system. *Biochemistry* **46**:3262–3269; 2007.
- [73] Hensley, K.; Christov, A.; Kamat, S.; Zhang, X. C.; Jackson, K. W.; Snow, S., et al. Proteomic identification of binding partners for the brain metabolite lantionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. *J. Neurosci* **30**:2979–2988; 2010.
- [74] Hensley, K.; Venkova, K.; Christov, A.; Gunning, W.; Park, J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodegeneration. *Mol. Neurobiol.* **43**:180–191; 2011.
- [75] Bishop, N. A.; Lu, T.; Yankner, B. A. Neural mechanisms of ageing and cognitive decline. *Nature* **464**:529–535; 2010.
- [76] Hughes, T.; Ganguli, M. Modifiable midlife risk factors for late-life dementia. *Rev. Neurol.* **51**:259–262; 2010.
- [77] Wimo A., Jonsson L., Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. *Dementia Geriatr. Cognit. Disord.* **21**:175–181; 2006.
- [78] Hopkins, R. O.; Brett, S. Chronic neurocognitive effects of critical illness. *Curr. Opin. Crit. Care* **11**:369–375; 2005.
- [79] Gil, D. V. Oxidative stress in aging: theoretical outcomes and clinical evidences in humans. *Biomed. and Aging Path.* **1**(1):1–7; 2010.
- [80] Ashok, B. T.; Ali, R. The aging paradox: free radical theory of aging. *Exp. Gerontol.* **34**:293–303; 1999.
- [81] Biesalski, H. K. Free radical theory of aging. *Curr. Opin. Clin. Nutr. Metab. Care* **5**:5–10; 2002.
- [82] Brown, A. M.; Ransom, B. R. Astrocyte glycogen and brain energy metabolism. *Glia* **55**:1263–1271; 2007.
- [83] Tscapopoulos, M.; Magistretti, P. J. Metabolic coupling between glia and neurons. *J. Neurosci.* **16**:877–885; 1996.
- [84] Christen, Y. Oxidative stress and Alzheimer disease. *Am. J. Clin. Nutr.* **71**:621S–629S; 2000.
- [85] Zimmerman, J. J. Defining the role of oxyradicals in the pathogenesis of sepsis. *Crit. Care Med.* **23**:616–617; 1995.
- [86] Voigt, K.; Kontush, A.; Stuerenburg, H. J.; Muench-Harrach, D.; Hansen, H. C.; Kunze, K. Decreased plasma and cerebrospinal fluid ascorbate levels in patients with septic encephalopathy. *Free Radic. Res.* **36**:735–739; 2002.
- [87] Girard, T. D.; Jackson, J. C.; Pandharipande, P. P.; Pun, B. T.; Thompson, J. L.; Shintani, A. K., et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. *Crit. Care Med.* **38**:1513–1520; 2010.
- [88] Ninkovic, M.; Malicevic, I.; Jelenkovic, A.; Jovanovic, D. M.; Dukic, M.; Vasiljevic, I. Oxidative stress in the rat brain capillaries in sepsis—the influence of 7-nitroindazole. *Acta Physiol. Hung.* **93**:315–323; 2006.
- [89] Comim, C. M.; Cassol Jr. O. J.; Constantino, L. S.; Felisberto, F.; Petronilho, F.; Rezim, G. T., et al. Alterations in inflammatory mediators, oxidative stress parameters and energetic metabolism in the brain of sepsis survivor rats. *Neurochem. Res.* **36**:304–311; 2011.
- [90] Ritter, C.; Andrades, M. E.; Reinke, A.; Menna-Barreto, S.; Moreira, J. C.; Dal-Pizzol, F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. *Crit. Care Med.* **32**:342–349; 2004.
- [91] Barichello, T.; Machado, R. A.; Constantino, L.; Valvassori, S. S.; Reus, G. Z.; Martins, M. R., et al. Antioxidant treatment prevented late memory impairment in an animal model of sepsis. *Crit. Care Med.* **35**:2186–2190; 2007.
- [92] Yamada, K.; Tanaka, T.; Han, D.; Senzaki, K.; Kameyama, T.; Nabeshima, T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1–42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. *Eur. J. Neurosci* **11**:83–90; 1999.
- [93] Gorelick, P. B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. *Ann. N. Y. Acad. Sci.* **1207**:155–162; 2010.
- [94] Lue, L. F.; Kuo, Y. M.; Beach, T.; Walker, D. G. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. *Mol. Neurobiol.* **41**:115–128; 2010.
- [95] Siami S., Annane D., Sharshar T. The encephalopathy in sepsis. *Crit. Care Clin.* **24**:67–82, viii; 2008.
- [96] Nguyen, D. N.; Spapen, H.; Su, F.; Schiettecatte, J.; Shi, L.; Hachimi-Idrissi, S., et al. Elevated serum levels of S-100 β protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. *Crit. Care Med.* **33**:1967–1974; 2006.
- [97] Sharshar, T.; Carlier, R.; Bernard, F.; Guidoux, C.; Brouland, J. P.; Nardi, O., et al. Brain lesions in septic shock: a magnetic resonance imaging study. *Intens. Care Med.* **33**:798–806; 2007.
- [98] Rosenberg, G. A. Inflammation and white matter damage in vascular cognitive impairment. *Stroke* **40**:S20–S23; 2009.
- [99] Bozza, F. A.; Garteiser, P.; Oliveira, M. F.; Doblas, S.; Cranford, R.; Saunders, D., et al. Sepsis-associated encephalopathy: a magnetic resonance imaging and spectroscopy study. *J. Cereb. Blood Flow Metab.* **30**:440–448; 2010.
- [100] Higgins, S. J.; Kain, K. C.; Liles, W. C. Immunopathogenesis of Falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria. *Expert Rev. Anti-Infect. Ther.* **9**:803–819; 2011.
- [101] de Souza, J. B.; Hafalla, J. C.; Riley, E. M.; Couper, K. N. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. *Parasitology* **137**:755–772; 2010.
- [102] Carter, J. A.; Mung'ala-Odera, V.; Neville, B. G.; Murira, G.; Mturi, N.; Musumba, C., et al. Persistent neurocognitive impairments associated with severe Falciparum malaria in Kenyan children. *J. Neurol. Neurosurg. Psychiatry* **76**:476–481; 2005.
- [103] Carter, J. A.; Ross, A. J.; Neville, B. G.; Obiero, E.; Katana, K.; Mung'ala-Odera, V., et al. Developmental impairments following severe Falciparum malaria in children. *Trop. Med. Int. Health* **10**:3–10; 2005.

- [104] Boivin, M. J.; Bangirana, P.; Byarugaba, J.; Opoka, R. O.; Idro, R.; Jurek, A. M., et al. Cognitive impairment after cerebral malaria in children: a prospective study. *Pediatrics* **119**:e360–e366; 2007.
- [105] John, C. C.; Bangirana, P.; Byarugaba, J.; Opoka, R. O.; Idro, R.; Jurek, A. M., et al. Cerebral malaria in children is associated with long-term cognitive impairment. *Pediatrics* **122**:e92–e99; 2008.
- [106] Schofield, L.; Grau, G. E. Immunological processes in malaria pathogenesis. *Nat. Rev. Immunol.* **5**:722–735; 2005.
- [107] Rest, J. R. Pathogenesis of cerebral malaria in golden hamsters and inbred mice. *Contrib. Microbiol. Immunol.* **7**:139–146; 1983.
- [108] Curfs, J. H.; Hermesen, C. C.; Kremsner, P.; Neifer, S.; Meuwissen, J. H.; Van, R. N., et al. Tumour necrosis factor- α and macrophages in Plasmodium berghei-induced cerebral malaria. *Parasitology* **107**(Pt 2):125–134; 1993.
- [109] Elamin, A. M. Cerebral malaria in adult Zambian Africans. *East Afr. Med. J.* **58**:124–129; 1981.
- [110] Pongponratn, E.; Riganti, M.; Harinasuta, T.; Bunnag, D. Electron microscopy of the human brain in cerebral malaria. *Southeast Asian J. Trop. Med. Public Health* **16**:219–227; 1985.
- [111] Porta, J.; Carota, A.; Pizzolato, G. P.; Wildi, E.; Widmer, M. C.; Margairaz, C., et al. Immunopathological changes in human cerebral malaria. *Clin. Neuropathol.* **12**:142–146; 1993.
- [112] Coltel, N.; Combes, V.; Hunt, N. H.; Grau, G. E. Cerebral malaria—a neurovascular pathology with many riddles still to be solved. *Curr. Neurovasc. Res.* **1**:91–110; 2004.
- [113] Hanum, P. S.; Hayano, M.; Kojima, S. Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain. *Int. Immunol.* **15**:633–640; 2003.
- [114] Favre, N.; Ryffel, B.; Rudin, W. The development of murine cerebral malaria does not require nitric oxide production. *Parasitology* **118**(Pt 2):135–138; 1999.
- [115] Miyazaki, Y.; Bunting, M.; Stafforini, D. M.; Harris, E. S.; McIntyre, T. M.; Prescott, S. M., et al. Integrin α Dbeta2 is dynamically expressed by inflamed macrophages and alters the natural history of lethal systemic infections. *J. Immunol.* **180**:590–600; 2008.
- [116] Reis, P. A.; Comim, C. M.; Hermani, F.; Silva, B.; Barichello, T.; Portella, A. C., et al. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. *PLoS Pathog.* **6**:e1000963; 2010.
- [117] Hensley, K.; Abdel-Moaty, H.; Hunter, J.; Mhatre, M.; Mou, S.; Nguyen, K., et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. *J. Neuroinflammation* **3**:2; 2006.
- [118] Hensley, K.; Mhatre, M.; Mou, S.; Pye, Q. N.; Stewart, C.; West, M., et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. *Antioxid. Redox Signaling* **8**:2075–2087; 2006.
- [119] Zhou, J.; Huang, W. Q.; Li, C.; Wu, G. Y.; Li, Y. S.; Wen, S. H., et al. Intestinal ischemia/reperfusion enhances microglial activation and induces cerebral injury and memory dysfunction in rats. *Crit. Care Med.* **40**:2438–2448; 2012.
- [120] Floyd, R. A.; Hensley, K.; Bing, G. Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics. *J. Neural Transm.* **60**:337–364; 2000.
- [121] Biegon, A.; Alvarado, M.; Budinger, T. F.; Grossman, R.; Hensley, K.; West, M. S., et al. Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. *J. Neurochem.* **82**:924–934; 2002.
- [122] Hainsworth, A. H.; Brittain, J. F.; Khatun, H. Pre-clinical models of human cerebral small vessel disease: utility for clinical application. *J. Neurol. Sci.* **322**:237–240; 2012.
- [123] Verret, L.; Mann, E. O.; Hang, G. B.; Barth, A. M.; Cobos, I.; Ho, K., et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. *Cell* **149**:708–721; 2012.
- [124] Zhang, Q. L.; Jia, L.; Jiao, X.; Guo, W. L.; Ji, J. W.; Yang, H. L., et al. APP/PS1 transgenic mice treated with aluminum: an update of Alzheimer's disease model. *Int. J. Immunopathol. Pharmacol.* **25**:49–58; 2012.
- [125] Barichello, T.; Santos, A. L.; Savi, G. D.; Generoso, J. S.; Otaran, P.; Michelon, C. M., et al. Antioxidant treatment prevents cognitive impairment and oxidative damage in pneumococcal meningitis survivor rats. *Metab. Brain Dis.* **27**:587–593; 2012.
- [126] Petronilho, F.; Perico, S. R.; Vuolo, F.; Mina, F.; Constantino, L.; Comim, C. M., et al. Protective effects of guanosine against sepsis-induced damage in rat brain and cognitive impairment. *Brain Behav. Immun.* **26**:904–910; 2012.
- [127] Comim, C. M.; Cassol, O. J.; Jr.; Abreu, I.; Moraz, T.; Constantino, L. S.; Vuolo, F. Erythropoietin reverts cognitive impairment and alters the oxidative parameters and energetic metabolism in sepsisanimal model. *J. Neural Transm.* **119**(11):1267–1274; 2012.
- [128] Barichello, T.; Lemos, J. C.; Generoso, J. S.; Carradore, M. M.; Moreira, A. P.; Collodel, A., et al. Evaluation of the brain-derived neurotrophic factor, nerve growth factor and memory in adult rats survivors of the neonatal meningitis by Streptococcus agalactiae. *Brain Res. Bull.* (in press).
- [129] Zimmerman, G. A.; Castro-Faria-Neto, H. Persistent cognitive impairment after cerebral malaria: models, mechanisms and adjunctive therapies. *Expert Rev. Anti-Infect. Ther.* **8**:1209–1212; 2010.
- [130] Fan, L.; Mitchell, H.; Tien, L.; Rhodes, P.; Cai, Z. Interleukin-1 β -induced brain injury in the neonatal rat can be ameliorated by α -phenyl-n-tert-butyl-nitronone. *Exp. Neurol.* **220**:143–153; 2009.
- [131] Garcia-Alloza, M.; Borrelli, L.; Hyman, B.; Bacskai, B. Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. *Neurobiol. Aging* **31**:2068; 2010.
- [132] D'Amore, J.; Kajdasz, S.; McLellan, M.; Bacskai, B.; Stern, E.; Hyman, B. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavin-S-associated alterations in neurite trajectories. *J. Neuropathol. Exp. Neurol.* **62**:137–145; 2003.
- [133] Spire, T.; Meyer-Luehmann, M.; Stern, E.; McLean, P.; Skoch, J.; Nguyen, P., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. *J. Neurosci.* **25**:7278–7287; 1990.
- [134] Masliah, E.; Terry, R.; DeTeresa, R.; Hansen, L. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. *Neurosci. Lett.* **103**:234–239; 1989.
- [135] Scheff, S.; DeKosky, S.; Price, D. Quantitative assessment of cortical synaptic density in Alzheimer's disease. *Neurobiol. Aging* **11**:29–37; 1990.
- [136] Lombardo, J.; Stern, E.; McLellan, M.; Kajdasz, S.; Hickey, G.; Bacskai, B., et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. *J. Neurosci.* **23**:10879–10883; 2003.
- [137] Stern, E.; Bacskai, B.; Hickey, G.; Attenello, F.; Lombardo, J.; Hyman, B. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. *J. Neurosci.* **24**:4535–4540; 2004.
- [138] Choi, C. H.; Chen, K.; Vasquez-Weldon, A.; Jackson, R. L.; Floyd, R. A.; Kopke, R. D. Effectiveness of 4-hydroxy phenyl N-tert-butyl-nitronone (4-OHPBN) alone and in combination with other antioxidant drugs in the treatment of acute acoustic trauma in chinchilla. *Free Radic. Biol. Med.* **44**:1772–1784; 2008.
- [139] Choi, C. H.; Chen, K.; Du, X.; Floyd, R. A.; Kopke, R. D. Effects of delayed and extended antioxidant treatment on acute acoustic trauma. *Free Radic. Res.* **45**:1162–1172; 2011.
- [140] Du, X.; Choi, C. H.; Chen, K.; Cheng, W.; Floyd, R. A.; Kopke, R. D. Reduced formation of oxidative stress biomarkers and migration of mononuclear phagocytes in the cochlea of chinchilla after antioxidant treatment in acute acoustic trauma. *Int. J. Otolaryngol.* **2011**:612690; 2011.
- [141] Du, X.; Chen, K.; Choi, C. H.; Li, W.; Cheng, W.; Stewart, C., et al. Selective degeneration of synapses in the dorsal cochlear nucleus of chinchilla following acoustic trauma and effects of antioxidant treatment. *Hear. Res.* **283**:1–13; 2011.
- [142] Mandal, M. N.; Moiseyev, G. P.; Elliott, M. H.; Kasus-Jacobi, A.; Li, X.; Chen, H., et al. Alpha-phenyl-N-tert-butyl-nitronone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity. *J. Biol. Chem.* **286**:32491–32501; 2011.
- [143] Ewert, D. L.; Lu, J.; Li, W.; Du, X.; Floyd, R.; Kopke, R. Antioxidant treatment reduces blast-induced cochlear damage and hearing loss. *Hear. Res.* **285**:29–39; 2012.